Securities Purchase Agreement
In connection with the closing of the Exchange Transaction, the Company and the Holder entered into a termination agreement dated September 27, 2021 with respect to the Securities Purchase Agreement, dated as of December 4, 2015 (the “Securities Purchase Agreement”), pursuant to which the Company and the Holder terminated the Securities Purchase Agreement and any amendment, annexes or exhibits thereto in all respects as of the Closing Date and agreed that no party thereto shall have any surviving obligations, rights or duties thereunder. The Securities Purchase Agreement is attached as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 8, 2015 and is incorporated herein by reference.
Item 3.02 | Unregistered Sales of Equity Securities |
Pursuant to the Securities Exchange Agreement, on the Closing Date, the Company issued 49,066,005 shares of Common Stock to the Holder in exchange for all of the outstanding Series E-1 Preferred and Series F-1 Preferred held by the Holder. The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended, for the issuance of the Common Stock in the Exchange Transaction described above.
Item 5.01 | Changes in Control of Registrant |
On the Closing Date, pursuant to the Exchange Transaction, the Holder acquired 49,066,005 shares of the Company’s Common Stock in exchange for all of the shares of Series E-1 Preferred and Series F-1 Preferred held by the Holder, which resulted in the Holder beneficially owning 53,135,329 shares of the Company’s Common Stock, or approximately 67% of the issued and outstanding Common Stock of the Company as of such date. The foregoing does not include the approximately 1,220,797 shares of Common Stock that are expected to be issued to the Holder on October 8, 2021 in connection with the Company’s previously announced special dividend of 0.3 shares of Common Stock for every one share outstanding on the record date of September 24, 2021 (the “Special Dividend”). The Holder maintains certain rights to, among other things, designate nominees for election as directors of the Company and set forth in the Board Representation and Standstill Agreement dated as of December 4, 2015, as amended on October 26, 2017 and October 18, 2018 and as further amended by the Amendment and Waiver to Board Representation and Standstill Agreement dated September 27, 2018. The Board Representation and Standstill Agreement is attached as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 8, 2015, the amendment thereto date October 26, 2017 is attached as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 26, 2017, the additional amendment thereto dated October 18, 2018 is attached as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 19, 2018, and the Amendment and Waiver to Board Representation and Standstill Agreement dated September 27, 2021 is attached hereto as Exhibit 10.1, and in each case is incorporated herein by reference.
-3-